Declaration Of Independence: Perlstein Lab Goes Solo Against Rare Diseases
Executive Summary
Unable to land an academic job and unwilling to work in industry, Ethan Perlstein is using 21st-century tools to bootstrap his rare-disease drug discovery platform. But can he raise a million dollars?
You may also be interested in...
AAVLife: Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
With AAVLife Debut, Another Gene Therapy Effort To Treat Friedreich's Ataxia
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
The Longest Round: NovImmune’s Eight-Year Series B
Several biotechs have kept a private financing round open for several years and extended beyond $100 million, but Swiss antibody firm NovImmune is taking the concept farther than anyone.